A Novel Tetravalent Bispecific Immune Cell Engager Activates Natural Killer Cells to Kill Cancer Cells without Mediating FratricideANTIBODIESIF2.72024-09-100OAAI
A high affinity and specificity anti-HER2 single-domain antibody (VHH) that targets trastuzumab's epitope with versatile biochemical, biological, and medical applicationsIMMUNOLOGIC RESEARCHIF3.12023-08-265OA
Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapyFRONTIERS IN IMMUNOLOGYIF5.92023-01-0626OAAI
Liposome-based nanocarriers loaded with anthrax lethal factor and armed with anti-CD19 VHH for effectively inhibiting MAPK pathway in B cellsINTERNATIONAL IMMUNOPHARMACOLOGYIF4.72021-11-0110PREAI
Multivalent targeting and killing of HER2 overexpressing breast carcinoma cells with methotrexate-encapsulated tetra-specific non-overlapping variable domain heavy chain anti-HER2 antibody-PEG-liposomes: In vitro proof-of-conceptEUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCESIF4.72018-09-0128PREAI
Effective suppression of tumour cells by oligoclonal HER2-targeted delivery of liposomal doxorubicinJOURNAL OF LIPOSOME RESEARCHIF4.32018-04-0627PREAI
Liposomal nanoparticle armed with bivalent bispecific single-domain antibodies, novel weapon in HER2 positive cancerous cell lines targetingMOLECULAR IMMUNOLOGYIF32018-04-0126PREAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向